Clinical Trials
12 trialsNCT05645718 2026-05-19
Study of Pedi-cRIB: Mini-Hyper-CVD With Condensed Rituximab, Inotuzumab Ozogamicin and Blinatumomab (cRIB) for Relapsed Therapy for Pediatric With B-Cell Lineage Acute Lymphocytic Leukemia
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT01169636 2021-01-06
Panobinostat Plus Ifosfamide, Carboplatin, and Etoposide (ICE) Compared With ICE For Relapsed Hodgkin Lymphoma
M.D. Anderson Cancer Center
Phase 1/2 Completed
NCT00671658 2020-12-03
Modified Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) Program for Acute Lymphoblastic Leukemia
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00101010 2020-10-19
Rituximab and Combination Chemotherapy in Treating Older Patients With Diffuse Large B-Cell Lymphoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02392039 2019-04-23
Study of Loratadine for Pegfilgrastim Induced Bone Pain in Patients With Aggressive Lymphoma
M.D. Anderson Cancer Center
Phase EARLY_PHASE1 Terminated
NCT02963389 2019-01-15
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Tripegfilgrastim in Pediatric Solid Tumor/Lymphoma Patients
Dong-A ST Co., Ltd.
Phase 1 Completed
NCT00069953 2017-02-17
Combination Chemotherapy Followed By Chemoradiotherapy, With or Without Surgery, in Treating Patients With Resectable Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction
Radiation Therapy Oncology Group
Phase 2 Completed
NCT03045627 2017-02-07
Clinical Trial of Ara-C, Aclarubicin Combined With PEG-G-CSF for Initial Treatment of AML Patients
Shandong University
Phase 2 Unknown
NCT02441894 2017-01-24
PEGAZUS
Sanofi
Phase 4 Completed
NCT01674855 2014-10-01
PEG-G-CSF
Dong-A ST Co., Ltd.
Phase 3 Completed
NCT01923545 2014-10-01
PEG-G-CSF
Dong-A ST Co., Ltd.
Phase 2 Completed
NCT00067639 2012-08-01
Pegfilgrastim (Neulasta) for Stem Cell Mobilization in Patients With Multiple Myeloma
M.D. Anderson Cancer Center
Phase 2 Completed